Results 71 to 80 of about 54,698 (337)
Radiopharmaceutical Therapy [PDF]
Abstract Radiopharmaceutical therapy involves the use of radionuclides that are either conjugated to tumor-targeting agents (e.g., nanoscale constructs, antibodies, peptides, and small molecules) or that concentrate in tumors through natural physiological mechanisms that occur predominantly in neoplastic cells.
openaire +2 more sources
Abstract Objectives An increasing body of evidence indicates altered DNA methylation in Parkinson's disease, yet the reproducibility and utility of such methylation changes are largely unexplored. We aimed to further elucidate the role of dysregulated DNA methylation in Parkinson's disease and to evaluate the biomarker potential of methylation‐based ...
Ingeborg Haugesag Lie+4 more
wiley +1 more source
Radiopharmaceuticals differ from other medicines mainly by the specific nature of their pharmacological action based on radioactivity, by absence of multiple-dose regimens, and by miniscule concentrations of the active pharmaceutical ingredient (10-9–10 ...
O. E. Klementyeva+2 more
doaj +1 more source
Evaluation of imaging protocol for ECT based on CS image reconstruction algorithm [PDF]
SPECT (Single-photon Emission Computerized Tomography) and PET (Positron Emission Tomography) are essential medical imaging tools, for which the sampling angle number, scan time should be chosen carefully to compromise between image quality and the radiopharmaceutical dose.
arxiv +1 more source
Early BMI Change, Cognitive Decline, and CSF AD Biomarkers Alterations in Parkinson's Disease
ABSTRACT Objective To examine the relationship of early BMI change with subsequent cognitive decline, CSF AD biomarkers alterations, and progression to dementia in patients with PD. Methods Study data were prospectively collected from the PPMI cohort. Weight/height data at enrollment and second‐year clinical visit were utilized to calculate BMI change.
Rui Zhong, Kezhong Zhang
wiley +1 more source
Development of 225Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences
Background: The development of radiopharmaceuticals containing 225Ac for targeted alpha therapy is an active area of academic and commercial research worldwide.
A. Robertson+3 more
semanticscholar +1 more source
This study investigates the integrated diagnostic and therapeutic strategy utilizing 89Zr/131I‐labeled tinurilimab for the management of malignant lung nodules, with a particular focus on lung adenocarcinoma (LUAD). CEACAM6, which is highly expressed in most LUAD patients, activates the Src/FAK signaling pathway, thereby promoting cell proliferation ...
Chongyang Chen+8 more
wiley +1 more source
Glutathione (GSH)‐activated prodrugs are promising for overcoming the limitations of conventional anti‐tumor drugs. However, current GSH‐responsive disulfide groups exhibit unregulated reactivity, making it impossible to precisely control the drug ...
Si‐Yu Wang+6 more
doaj +1 more source
In order to seek novel technetium-99m folate receptor-targeting agents, two folate derivatives (CN5FA and CNPFA) were synthesized and radiolabeled to obtain [99mTc]Tc-CN5FA and [99mTc]Tc-CNPFA complexes, which exhibited high radiochemical purity (>95 ...
Junhong Feng+4 more
doaj +1 more source
Polycrystalline para-terphenyl scintillator adopted in a $β^-$ detecting probe for radio-guided surgery [PDF]
A radio-guided surgery technique exploiting $\beta^-$ emitters is under development. It aims at a higher target-to-background activity ratio implying both a smaller radiopharmaceutical activity and the possibility of extending the technique to cases with a large uptake of surrounding healthy organs.
arxiv +1 more source